Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
Symptom-onset dosing with a serotonin reuptake inhibitor for PMDD may have a greater impact on anger/irritability and relationship functioning than other symptoms.
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
There is evidence that depression itself can increase risk for hypertension and preeclampsia. Future studies will help to clarify the complex interaction between depression, SSRI treatment and pre-eclampsia.
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
Many women experience depression during pregnancy. What is the best way to identify these women?
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on clinical issues regarding prescribing antidepressants during pregnancy with Ob.Gyn News on March 23, [...]
While questions and controversies remain, the information on long-term neurodevelopmental outcomes in children prenatally exposed to antidepressants is largely reassuring.
SSRI and SNRI antidepressants were not associated with an increased risk for gestational diabetes.
